Analysts Appear Bullish on Thermo Fisher (TMO): Is The Stock Really a Buy After Earnings?

Thermo Fisher Scientific (TMO) recently reported strong Q2 2026 results, with revenue up 10% and adjusted EPS up 13%, leading analysts to raise price targets. The company's product innovation and recovery in its Life Sciences Solutions and Analytical Instruments segments fueled optimism, despite the stock's premium valuation and the need for continued strong performance to justify it. Hedge fund sentiment also shows increased confidence, with management raising full-year revenue guidance.